Abbisko的pimicotinib显示在治疗TGCT方面取得显著成功,在第三阶段试验中答复率为54%。 Abbisko's pimicotinib shows significant success in treating TGCT, with a 54% response rate in Phase 3 trials.

Abbisko的药物Pimicotinib显示,在第三阶段研究中,在治疗乳房巨型细胞肿瘤(TGCT)方面有重大改进。 Abbisko's drug, pimicotinib, has shown significant improvements in treating tenosynovial giant cell tumor (TGCT) in a Phase 3 study. 该药物在第25周达到54%的客观回复率,而安慰剂的响应率为3.2%。 The drug achieved a 54% objective response rate at Week 25, compared to 3.2% for the placebo. 它还改善了疼痛和僵硬程度,由于副作用,停业率较低。 It also improved pain and stiffness, with low discontinuation rates due to side effects. 这一突破性试验包括亚洲和西方病人,提高了不同人群对该疾病的认识。 This breakthrough trial included both Asian and Western patients, enhancing understanding of the disease across different populations.